Breast Cancer Therapeutics Market to Exhibit 13.1% CAGR till 2027; Novartis Receives USFDA Approval for Piqray to Treat Advanced Breast Cancer

The global breast cancer therapeutics market size is projected to reach USD 55.27 billion by 2027. The rising inclusion of new patients in the treatment process and the surging sales of various breast cancer therapeutics drugs will affect growth positively in the near future. Fortune Business Insights™ provided this information in a new report, titled, “Breast Cancer Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Therapy (Targeted Therapy, Hormonal Therapy, Chemotherapy, and Immunotherapy), By Cancer Type (Hormone Receptor, and HER2+), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), and Regional Forecast, 2020-2027.” The report further states that the market stood at USD 21.58 billion in 2019. It would exhibit a CAGR of 13.1% during the forecast period between 2020 to 2027.

USFDA Approves Roche’s Phesgo for Treating Metastatic HER2-positive Breast Cancer

In July 2020, Roche Holding AG, a healthcare company headquartered in Basel, announced that it bagged the USFDA approval for Phesgo. It is a fixed-dose combination of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) with hyaluronidase. It will be administered by under the skin injection with intravenous (IV) chemotherapy and will be used to treat early and metastatic HER2-positive breast cancer.

According to one of the company officials, “This approval is based on the results of the phase 3 FeDeriCa study. The phase 2 study revealed that 85% of people receiving treatment for breast cancer preferred under the skin to IV administration owing to more comfortable treatment administration and less time in the clinic.”

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/breast-cancer-therapeutics-market-100163

Increasing Awareness Programs to Educate People will Bolster Growth

The rising demand for early treatment and preventive care is set to result in the rapid shift of people towards cancer screening tests. In addition to that, various government and private agencies are creating awareness programs worldwide to educate the masses about the availability of this type of cancer therapeutics that are very effective.

Moreover, the rising incidence of breast cancer across the globe would also contribute to the breast cancer therapeutics market growth in the near future. The World Cancer Research Fund (WCRF), for instance, mentioned that approximately 2,088,849 new cases of breast cancer were diagnosed globally in 2018. However, the COVID-19 pandemic has compelled healthcare institutions to either cancel or postpone the breast cancer therapeutics procedures in many countries. It may obstruct growth.

Significant Strategies of Key Companies — Product Launches and New Approvals

The global market contains multiple renowned companies, such as Genentech, Novartis AG, Pfizer Inc., and AstraZeneca. They are mainly aiming to enhance their product portfolios by developing innovative drugs to cure breast cancer. Some of the others are striving persistently to achieve approvals from the USFDA to market their products.

Fortune Business Insights™ presents a list of all the prominent therapeutics providers operating in the global market. They are as follows:

• Genentech (F. Hoffmann-La Roche Ltd) (South San Francisco, U.S.)


• Eli Lilly and Company (Indianapolis, U.S.)


• Novartis AG (Basel, Switzerland)


• AstraZeneca (Cambridge, U.K.)


• Pfizer Inc. (New York City, U.S.)


• Sanofi (Paris, France)


• Eisai Co. Ltd. (Tokyo, Japan)


• Kyowa Kirin (Tokyo, Japan)


• Bristol Myers Squibb (Celgene Corporation) (New York City, U.S.)


• Merck & Co., Inc. (Kenilworth, U.S.)


• Other Players

A Noteworthy Industry Development-

• May 2019: Novartis, a multinational pharmaceutical company based in Switzerland, declared that it received approval from the U.S. Food and Drug Administration (FDA) for Piqray. It can be blended with fulvestrant to treat postmenopausal men and women with HR+/HER2-, metastatic or advanced breast cancer. It is considered to be the first treatment meant especially for HR+/HER2- advanced breast cancer.

Further Report Findings-

• In 2019, North America held USD 10.34 billion in terms of revenue in this market. The region is expected to remain in the forefront because of the high healthcare expenditure and rising usage of advanced therapeutics.


• Europe would remain in the second position on the account of increasing launch of innovative breast cancer therapeutics in the region. At the same time, the surging adoption of state-of-the-art drugs in the region is likely to aid growth.


• Based on therapy, the hormonal therapy segment generated 8.3% in terms of the breast cancer therapeutics share in 2019. The segment would show low growth fueled by the availability of their generic equivalents in the market.

The global market can be segmented in the following way: